微信小陈
微信小章| 产品名称： | AtT-20ins (CGT-6) |
|---|---|
| 商品货号： | TS212649 |
| Organism： | Mus musculus, mouse |
| Product Format： | frozen |
| Morphology： | spindle shape |
| Culture Properties： | adherent |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | sarcoma |
| Strain： | LAF1 |
| Applications： | This line was derived from an AtT-20ins cell line in which the Rous sarcoma virus long terminal repeat was used for directing insulin cDNA expression. The cell line produces glucose-stimulated insulin release in both static incubation and perifusion studies. The cell line is resistant to 0.25 mg/ml G-418 and 0.12 mg/ml hygromycin B. The presence of the GLUT-2 transgene can be confirmed by Northern blot analysis. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | This line was derived from an AtT-20ins cell line in which the Rous sarcoma virus long terminal repeat was used for directing insulin cDNA expression. |
| Genes Expressed： | insulin |
| Cellular Products： | insulin |
| Comments： | This line was derived from an AtT-20ins cell line in which the Rous sarcoma virus long terminal repeat was used for directing insulin cDNA expression. AtT-20ins cells were transfected by eclectroporation with rat islet GLUT-2 cDNA cloned into the vector pCB-7 immediately downstream of its cytomegalovirus promotor. The pCB-7 vector contains a hygromycin resistance marker. The cell line produces glucose-stimulated insulin release in both static incubation and perifusion studies. The cell line is resistant to 0.25 mg/ml G-418 and 0.12 mg/ml hygromycin B. The presence of the GLUT-2 transgene can be confirmed by Northern blot analysis. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Subcultivation Ratio: A subcultivation ratio of 1:4 is recommended Medium Renewal: Every 2 to 3 days Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. |
| Cryopreservation： | FBS, 50%; Complete growth medium ,40%; DMSO, 10% |
| Culture Conditions： | Temperature: 37.0°C |
| Name of Depositor： | Univ. Texas System |
| Deposited As： | mouse |
| U.S. Patent Number： | |
| References： | Newgard CR. Methods of using genetically engineered cells that produce insulin in response to glucose. US Patent 5,993,799 dated Nov 30 1999 Hughes SD, et al. Engineering of glucose-stimulated insulin secretion and biosynthesis in non-islet cells. Proc. Natl. Acad. Sci. USA 89: 688-692, 1992. PubMed: 1309953 Inman LR, et al. Autoantibodies to the GLUT-2 glucose transporter of beta cells in insulin-dependent diabetes mellitus of recent onset. Proc. Natl. Acad. Sci. USA 90: 1281-1284, 1993. PubMed: 8433987 Hughes SD, et al. Transfection of AtT-20ins cells with GLUT-2 but not GLUT-1 confers glucose-stimulated insulin secretion. Relationship to glucose metabolism. J. Biol. Chem. 268: 15205-15212, 1993. PubMed: 8325893 Schnedl WJ, et al. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 43: 1326-1333, 1994. PubMed: 7926307 |